Overview: Mircera is used to treat anemia. Common side effects include diarrhea and pain or swelling in the nose or throat. Serious side effects are rare but include blood clots, seizures, and severe ...

Results from two recent studies show for the first time that chronic kidney disease patients on dialysis as well as those not on dialysis, who need correction of renal anemia, were effectively treated ...

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins in the blood. Austrian researchers have successfully developed a new ...

A big plus for Roche today after the European Commission issued a final positive decision for its once- or twice-monthly anaemia drug Mircera for use in chronic kidney disease patients that is valid ...

New data for Roche’s anaemia drug Mircera confirm that the drug can raise haemoglobin levels in the blood with twice-monthly dosing, suggesting it will mount a strong challenge to current treatments ...

Swiss firms Roche and Vifor Pharma have extended an agreement related to the marketing of Mircera (methoxy polyethylene glycol-epoetin beta) in the USA. The deal provides Vifor with: “Access to ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...